Fetal Twin-to-Twin Transfusion Syndrome (TTTS) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱ 7 min read ✅ Medically reviewed
```html Fetal Twin‑to‑Twin Transfusion Syndrome (TTTS) – A Complete Guide

Overview

Twin‑to‑Twin Transfusion Syndrome (TTTS) is a serious complication of monochorionic (single‑placenta) twin pregnancies. In TTTS, abnormal vascular connections in the shared placenta cause an imbalance of blood flow between the twins: one twin (the “donor”) gives up blood, while the other (the “recipient”) receives too much. This can lead to rapid growth restriction for the donor and heart‑failure‑type changes for the recipient.

  • Who it affects: Only twins that share a single placenta—primarily identical (monozygotic) twins.
  • Prevalence: TTTS occurs in about 10–15% of monochorionic diamniotic (MCDA) twin pregnancies, which represent roughly 0.3–0.5% of all pregnancies. That translates to ~1–2 cases per 1,000 total births.1
  • Typical timing: The condition usually becomes evident between 16 and 26 weeks of gestation, with peak incidence around 20 weeks.2

Symptoms

Because TTTS involves the fetuses, the mother’s symptoms are often subtle. The most reliable clues come from ultrasound findings, but several maternal signs may raise suspicion.

Maternal Symptoms

  • Rapid uterine growth: The uterus may enlarge faster than expected for gestational age.
  • Sudden increase in abdominal size: Often noted after 20 weeks.
  • Decreased fetal movement: Particularly if the donor twin becomes growth‑restricted.
  • Preterm contractions or pre‑term labor: TTTS can trigger early labor.
  • Unexplained swelling (edema) or shortness of breath: May reflect the recipient twin’s fluid overload (polyhydramnios).

Fetal Ultrasound Findings (the hallmark)

  • Discordant amniotic fluid volumes: Polyhydramnios (excess fluid) surrounding the recipient twin and oligohydramnios (scarcity of fluid) around the donor.
  • Size discrepancy: Donor twin is often smaller (growth restriction) while the recipient may be larger.
  • Cardiac changes in the recipient: Thickened cardiac walls, cardiomegaly, or signs of heart failure.
  • Umbilical artery Doppler abnormalities: Absent or reversed end‑diastolic flow in the donor twin.
  • Placental “vascular laser” pattern: Visible vascular anastomoses on detailed imaging.

Causes and Risk Factors

Pathophysiology

In a monochorionic placenta, tiny blood vessels (anastomoses) connect the circulations of the two fetuses. When the balance of these vessels tips toward unidirectional flow, one twin constantly loses blood (donor) while the other receives a net gain (recipient). The exact trigger for this imbalance is not fully understood, but it is believed to involve:

  • Unequal number or size of arterio‑arterial, arterio‑venous, or venous‑venous connections.
  • Differences in fetal cardiac output and vascular resistance.
  • Placental growth patterns that favor one twin.

Risk Factors

  • Monochorionic diamniotic twins: By definition, the only pregnancies at risk.
  • Higher order monochorionic multiples: Triplets or more increase the complexity of placental sharing.
  • Previous TTTS pregnancy: Recurrence risk of ~15–20% in a subsequent monochorionic pregnancy.
  • Maternal age: Slightly higher incidence in women >35 years, likely because of higher rates of assisted reproductive technologies.
  • Assisted reproductive technology (ART): IVF and embryo transfer increase monochorionic twin rates, indirectly raising TTTS risk.

Diagnosis

Diagnosis relies on a combination of routine obstetric screening and specialized imaging.

Ultrasound

Transabdominal or transvaginal ultrasound is the gold standard. The criteria, known as the Quintero staging system, classify severity from Stage I (mild) to Stage V (fatal).

  1. Stage I: Polyhydramnios (Doppler Deepest Vertical Pocket > 8 cm) and oligohydramnios (pocket < 2 cm) with normal fetal bladders.
  2. Stage II: Donor’s bladder no longer visible.
  3. Stage III: Abnormal Doppler studies (absent/reversed end‑diastolic flow in the umbilical artery, or ductus venosus abnormalities).
  4. Stage IV: Hydrops (fluid accumulation) in the recipient twin.
  5. Stage V: Demise of one or both fetuses.

Additional Tests

  • Doppler Flow Studies: Assess blood‑flow direction in arteries and veins.
  • Fetal Echocardiography: Evaluates the recipient’s heart for signs of strain.
  • Maternal Blood Tests: While not diagnostic, they help rule out infections or maternal conditions that could mimic TTTS.

Treatment Options

Management is individualized based on gestational age, TTTS stage, and the twins’ condition. Early detection dramatically improves survival (up to 70% overall vs. <10% without treatment). Options include:

1. Fetoscopic Laser Photocoagulation (FLP)

  • What it is: A tiny endoscope is inserted through the mother’s abdomen into the amniotic fluid. A laser is used to seal the shared placental vessels.
  • Ideal timing: 16–26 weeks, usually before Stage III.
  • Success rates: 60–80% survival of both twins; reduces progression to higher stages.3
  • Risks: Premature premature rupture of membranes (PPROM), preterm birth, infection, or rare maternal complications.

2. Serial Amnioreduction

  • Procedure: Removal of excess amniotic fluid from the recipient’s sac to relieve uterine pressure and reduce preterm labor risk.
  • When used: When laser is unavailable or contraindicated, or as a bridge before definitive therapy.
  • Limitations: Does not treat the underlying vascular imbalance; multiple taps often needed.

3. Medical Management

  • Tocolytics: Medications (e.g., nifedipine) may be given to delay preterm labor after procedures.
  • Corticosteroids: Betamethasone or dexamethasone to accelerate fetal lung maturity if early delivery is anticipated (typically given between 24–34 weeks).
  • Maternal hydration & bed rest: Helpful adjuncts but have limited evidence.

4. Expectant Management (Close Monitoring)

In very early (<16 weeks) or very late (>30 weeks) presentations, or when the disease is Stage I and stable, physicians may opt for close ultrasound surveillance every 1–2 weeks.

5. Delivery Planning

  • Preterm delivery: If fetal distress progresses, delivery by cesarean section (often 34–36 weeks) may be recommended.
  • Neonatal care: Coordination with a tertiary NICU experienced in caring for premature twins is essential.

Living with Fetal Twin‑to‑Twin Transfusion Syndrome (TTTS)

Beyond medical procedures, families face emotional, logistical, and practical challenges.

Emotional support

  • Seek counseling or join support groups (e.g., TTTS Foundation, local perinatal loss groups).
  • Consider a mental‑health professional familiar with high‑risk obstetrics.

Practical tips

  • Appointment tracking: Keep a calendar of every ultrasound, lab, and procedure.
  • Medication schedule: Use a pillbox or phone reminders for steroids, tocolytics, or prenatal vitamins.
  • Nutrition & hydration: Maintain balanced meals; adequate fluid intake supports amniotic fluid balance.
  • Rest: Limit strenuous activity, especially after fetoscopic procedures.
  • Travel: Discuss with your provider; most recommend staying within 1–2 hours of the treating hospital after a laser procedure.

Preparing for possible preterm birth

  • Pack a hospital bag (including NICU‑specific items like a baby carrier for twins, double‑nursing bras, and snacks).
  • Arrange childcare for older siblings.
  • Confirm insurance coverage for NICU stay; request pre‑authorization early.

Prevention

Because TTTS arises from the shared placenta’s anatomy, true primary prevention is not possible. However, several strategies can lower risk or enable earlier detection.

  • Early and accurate chorionicity determination: First‑trimester ultrasound should confirm whether twins are monochorionic; this determines surveillance intensity.
  • Targeted screening: Monochorionic twins should undergo serial ultrasounds every 1–2 weeks from 16 weeks onward, per ACOG guidelines.4
  • Optimizing ART practices: Elective single embryo transfer reduces the incidence of multiple pregnancies and therefore TTTS.
  • Maternal health optimization: Good control of hypertension, diabetes, and smoking cessation improve overall placental health.

Complications

If TTTS is not treated—or if treatment fails—the following complications can arise.

For the donor twin

  • Severe intrauterine growth restriction (IUGR)
  • Renal agenesis or oliguria
  • Fetal demise (most common in advanced stages)

For the recipient twin

  • Cardiomegaly and heart failure
  • Polyhydramnios leading to premature labor
  • Fetal hydrops (fluid accumulation in chest/abdomen)
  • Neurological injury from chronic high‑output cardiac state

For the pregnancy

  • Preterm birth (average 32–34 weeks for treated cases, <28 weeks if untreated)
  • Placental abruption
  • Maternal complications from invasive procedures (infection, bleeding)

Long‑term outcomes

Survivors of TTTS have higher rates of neurodevelopmental impairment (cognitive or motor delay) compared with uncomplicated twins, especially when the disease was Stage III–IV or required early delivery.5 Ongoing pediatric follow‑up is recommended.

When to Seek Emergency Care

Call your obstetrician immediately or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain or cramping that does not subside with rest.
  • Vaginal bleeding or spotting heavier than a light brown “spot.”
  • Rapid increase in abdominal size accompanied by shortness of breath.
  • Leakage of fluid from the vagina (possible premature rupture of membranes).
  • Reduced fetal movements described as “less than usual” or “no movement for more than 2 hours.”
  • Fever >100.4 °F (38 °C) with chills, suggesting infection after an invasive procedure.
  • Signs of preterm labor: regular contractions (every 5–10 minutes), pelvic pressure, or a change in vaginal discharge.

Prompt evaluation can prevent progression to higher stages of TTTS or avoid preterm birth complications.

References

  1. Mayo Clinic. Twin-to-twin transfusion syndrome. 2023. https://www.mayoclinic.org/diseases‑conditions/twin‑to‑twin‑transfusion‑syndrome
  2. American College of Obstetricians and Gynecologists (ACOG). Management of Monochorionic Multiple Pregnancies. Practice Bulletin No. 175, 2020.
  3. Rossi AC, et al. Fetoscopic laser surgery for twin‑to‑twin transfusion syndrome: a systematic review and meta‑analysis. Placenta. 2022;115:1‑9.
  4. Centers for Disease Control and Prevention (CDC). Twin Pregnancy and the Risks of Complications. 2022.
  5. Quintero RA, et al. Long‑term neurodevelopmental outcome after treatment of TTTS. Journal of Perinatology. 2021;41(8):2021‑2028.
```

⚠ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References